David R. Gandara

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp et al. · The Lancet · 2016 · 4.8K citations · Full text

Medicine, Oncology, Pharmacology +13

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel et al. · Journal of Clinical Oncology · 2008 · 3.2K citations

Medicine, Oncology, Pharmacology +16

Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

Timothy Winton, Robert B. Livingston, David C. Johnson et al. · New England Journal of Medicine · 2005 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

Kathy S. Albain, Ruth Swann, Valerie W. Rusch et al. · The Lancet · 2009 · 1.5K citations

Medicine, Oncology, Surgery +16

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard et al. · The Lancet Oncology · 2015 · 1.4K citations

Medicine, Immunology, Oncology +17